Changes in the expression of pituitary adenylate cyclase-activating polypeptide in the human placenta during pregnancy and its effects on the survival of JAR choriocarcinoma cells.
Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide with survival-promoting actions, has been observed in endocrine organs and is thought to play a role in reproductive functions, including pregnancy. PACAP occurs in two forms, 27 and 38 amino acid residues, with PACAP38 being the predominant form in human tissues. In the present study, we determined the concentrations of PACAP38 and PACAP27 in first-trimester and full-term human placentas using radioimmunoassay. We found high levels of PACAP38 and lower levels of PACAP27 in different parts of the full-term human placenta. PACAP38 content increased in the placenta during pregnancy, both on the maternal side and on the fetal side. The effects of PACAP on the survival of JAR human choriocarcinoma cells were investigated using flow cytometry and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) cell viability assay in cells exposed to the widely used chemotherapeutic agent methotrexate (MTX). It was found that PACAP neither influenced the survival of JAR cytotrophoblast cells nor affected cellular response to the death-inducing effect of the chemotherapeutic agent MTX. The present observations further support the significance of PACAP in the human placenta. The observation that PACAP did not influence the effects of MTX may have future clinical importance, showing that PACAP does not decrease the effects of certain chemotherapeutic agents.
Brubel
R
R
Department of Anatomy, University of Pecs, Szigeti u 12, Pecs, Hungary.
Boronkai
A
A
Reglodi
D
D
Racz
B
B
Nemeth
J
J
Kiss
P
P
Lubics
A
A
Toth
G
G
Horvath
G
G
Varga
T
T
Szogyi
D
D
Fonagy
E
E
Farkas
J
J
Barakonyi
A
A
Bellyei
Sz
S
Szereday
L
L
Koppan
M
M
Tamas
A
A
D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D002822:Choriocarcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000378:metabolism* / Q000494:pharmacology*; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D020033:Protein Isoforms / Q000378:metabolism / Q000494:pharmacology; D011863:Radioimmunoassay; D011897:Random Allocation
D007166:Immunosuppressive Agents; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D020033:Protein Isoforms; D008727:Methotrexate
Br J Cancer. 2005 Apr 25;92(8):1506-16
15846300
Endocrinology. 1991 Nov;129(5):2787-9
1935809
Endocrinology. 2003 Apr;144(4):1631-43
12639948
J Mol Neurosci. 2008 Nov;36(1-3):270-8
18607779
Regul Pept. 1996 Mar 22;61(3):197-204
8701036
Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74
2803320
Mol Reprod Dev. 2003 Jan;64(1):27-31
12420296
Acta Biochim Pol. 2004;51(4):1023-38
15625574
Regul Pept. 2002 Nov 15;109(1-3):115-25
12409223
Neuroscience. 2008 Aug 13;155(2):387-402
18590802
Endocrinology. 2000 Mar;141(3):1158-67
10698193
Cell Tissue Res. 1998 Jan;291(1):65-79
9394044
Dev Neurosci. 2002;24(1):14-23
12145407
Mol Cell Endocrinol. 2008 Jan 2;280(1-2):13-9
17945412
Peptides. 2005 Nov;26(11):2344-50
15927304
Ann N Y Acad Sci. 2006 Jul;1070:348-53
16888190
J Neurosci Res. 2002 Mar 1;67(5):566-73
11891769
Comp Biochem Physiol C Toxicol Pharmacol. 2001 May;129(1):25-34
11369298
Peptides. 2007 Sep;28(9):1680-7
17467121
J Mol Neurosci. 2003 Apr;20(2):141-52
12794308
Cancer Res. 1995 Nov 1;55(21):4886-91
7585525
Curr Pharm Des. 2004;10(23):2861-89
15379674
Gen Comp Endocrinol. 2007 Aug-Sep;153(1-3):115-23
17270184
Peptides. 2007 Sep;28(9):1797-804
17601637
Ann N Y Acad Sci. 2009 Apr;1163:353-7
19456358
Br J Pharmacol. 2003 Jul;139(5):1050-8
12839880
J Biochem Biophys Methods. 2004 Oct 29;61(1-2):189-98
15560935
Peptides. 2006 Apr;27(4):743-52
16181705
Pharmacol Rev. 2009 Sep;61(3):283-357
19805477
Regul Pept. 2002 Nov 15;109(1-3):49-55
12409214
Am J Pathol. 1999 Dec;155(6):1893-900
10595920
J Vet Sci. 2005 Mar;6(1):1-5
15785117
J Mol Neurosci. 2010 Nov;42(3):419-27
20405239
Peptides. 2006 Jan;27(1):87-94
16095757
Mol Cell Endocrinol. 1994 Feb;99(1):31-7
7514549
Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):225-30
17286974
Neurobiol Dis. 2008 Oct;32(1):66-80
18652895
J Neuroimmunol. 2004 Apr;149(1-2):167-81
15020077
Cancer Res. 2006 Sep 1;66(17):8796-803
16951196
Ann N Y Acad Sci. 2000;921:400-4
11193864
Reprod Toxicol. 2001 May-Jun;15(3):253-60
11390169
Regul Pept. 2002 Nov 15;109(1-3):45-8
12409213
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4758-63
11296303
Brain Res. 2008 Nov 19;1241:29-35
18835258